Bioengineering platforms for cell therapeutics derived from pluripotent and direct reprogramming.

Pluripotent and direct reprogramming technologies hold great potential for tissue repair and restoration of tissue and organ function. The implementation of induced pluripotent stem cells and directly reprogrammed cells in biomedical research has resulted in a significant leap forward in the highly promising area of regenerative medicine. While these therapeutic strategies are promising, there are several obstacles to overcome prior to the introduction of these therapies into clinical settings. Bioengineering technologies, such as biomaterials, bioprinting, microfluidic devices, and biostimulatory systems, can enhance cell viability, differentiation, and function, in turn the efficacy of cell therapeutics generated via pluripotent and direct reprogramming. Therefore, cellular reprogramming technologies, in combination with tissue-engineering platforms, are poised to overcome current bottlenecks associated with cell-based therapies and create new ways of producing engineered tissue substitutes. © 2021 Author(s).

Citation

Yoonhee Jin, Seung-Woo Cho. Bioengineering platforms for cell therapeutics derived from pluripotent and direct reprogramming. APL bioengineering. 2021 Sep;5(3):031501

PMID: 34258498

search → result